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AIMS
Adverse drug reactions are a common problem affecting adults and children. The economic impact of the adverse drug reactions has
been widely evaluated; however, studies of the impact on the quality of life of children with adverse drug reactions are scarce. The aim
was to evaluate studies assessing the health-related quality of life of children with adverse drug reactions.

METHODS
We conducted a systematic review that included the following electronic databases: MEDLINE, EMBASE and the Cochrane Library
(including the Cochrane Database of Systematic Reviews, the Database of Abstracts of Reviews of Effects, the Cochrane Controlled
Trials Register and the Health Technology Assessment Databases).

RESULTS
Nine studies were included. Four of the studies were conducted in children with epilepsy; the rest of them involved children with
chronic viral hepatitis, Crohn’s disease, paediatric cancer and multiple adverse drug reactions compared with healthy children. Based
on their findings, authors of all studies concluded that adverse drug reactions had a negative impact on the quality of life of children.
No meta-analysis was conducted given the heterogeneous nature of the studies.

CONCLUSIONS
To date, there is no specific instrument that measures quality of life of children with adverse drug reactions, and the information
available is poor and variable. In general, adverse drug reactions have a negative impact on the quality of life of affected children. For
those interested in this area, more work needs to be done to improve tools that help to evaluate efficiently the health-related quality
of life of children with adverse drug reactions and chronic diseases.

Introduction
An adverse drug reaction (ADR) is defined as any noxious
or unintended reaction to a drug that is administered in
standard doses by the proper route for the purpose of
prophylaxis (e.g. vaccines), diagnosis (e.g. contrast media)
or treatment (e.g. antibiotics) [1, 2]. They can be classified
as type A when the reaction results from an exaggeration
of the normal pharmacological actions of a medication (i.e.
side-effect) and type B when the reaction is an unusual
© 2014 The British Pharmacological Society

response (i.e. idiosyncratic reaction) [3]. A more descriptive
classification is shown in Table 1 [2].
Adverse drug reactions are a common problem and are
recognized as an important cause of morbidity and mortality in patients of all ages, notably among hospitalized
patients and patients with chronic diseases [4]. The prevalence of ADRs seems to be higher among infants, women
and elderly patients. Among both children and adults,
some of the risk factors that have been suggested are
immaturity or impairment of drug clearance, off-label drug
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Table 1
Classification of adverse drug reactions (adapted from [2])

Predictable or reaction that may occur in anyone
Drug Overdose

Toxic reactions linked to excess dose or impaired
excretion or both
Undesirable pharmacological effect at recommended
dose

Drug side-effect

Drug interaction

Action of a drug on the effectiveness of toxicity of
another drug

use, certain genetic polymorphisms, age, gender, associated illnesses and the number of drugs to which patients
are exposed [5–7].
The incidence and prevalence vary greatly depending
on the country, age, population and criteria used to classify
the ADRs. In 1999, a prospective study of adverse drug
reactions in hospitalized children reported a cumulative
incidence of ADRs of 16.6% in a 2 year period [8]. Two years
later, a systematic review and meta-analysis of prospective
studies evaluating the incidence of ADRs in paediatric inand outpatients showed an overall incidence of ADRs
of 9.5% in hospitalized children; 12.9% of them were
reported as severe reactions [7]. The overall rate of paediatric hospital admissions due to ADRs was 2%, of which
39.3% of the ADRs were life-threatening reactions. For outpatient children, the overall incidence of ADRs was 1.5%.
More recently, diverse authors have reported an overall
incidence of ADRs among hospitalized children between
0.7% and 1.6%, whereas in outpatient settings it ranges
from 0.3% to 0.5% [9–11]. It is estimated that between
0.4% and 0.5% of all admissions in children result from an
ADR [9–11]. However, the incidence might be higher than
reported. For example, in Canada, the Department of
National Health and Welfare established the Drug Adverse
Reaction Reporting Program in 1965 [12]. However,
despite this system being in place, health-related accreditation bodies currently estimate that as many as 95% of all
adverse drug reactions are not reported [13].
Nevertheless, in spite of the lack of adequate methods
of classification and under-reporting of ADRs, the available
information is sufficient to support the belief that ADRs
represent a substantial healthcare problem with a significant associated healthcare cost [9, 11, 14]. In the USA, the
costs due to ADRs represent more than $300 million yearly
[5] while other authors report, also in the USA, that the
annual cost of managing ADRs among hospitalized adults
ranges between $1.6 billion and $4.2 billion [9]. Regarding
children, cost implications of ADRs in hospitalized children
(New Zealand) had an annual cost of $NZ235 214, with
828

/

80:4

/

Br J Clin Pharmacol

Unpredictable or reactions that occur only in susceptible subjects
Drug intolerance
Drug idiosyncrasy

A low threshold to the normal pharmacological action
of a drug
A genetically determined, qualitatively abnormal
reaction to a drug related to metabolic or enzymatic
deficiency

Drug allergy

An immunologically mediated reaction, characterized
by specificity, transferability by antibodies or
lymphocytes and recurrence on re-exposure

Pseudo-allergic reaction

A reaction with the same clinical manifestation as an
allergic reaction but lacking immunological specificity

33% of ADRs potentially resulting in persistent disability
[15]. Although numerous studies have evaluated the epidemiological and economic impact of ADRs, there have
been very few attempts to assess objectively and accurately the impact of ADRs on health-related quality of life
of patients who have suffered an undesirable effect secondary to therapy, in particular among children.
In addition to the economic impact, ADRs can
adversely affect the function of patients and negatively
impact their life. The World Health Organization and the
International League against Rheumatism define quality of
life (QoL) as ‘the perception of individuals of their own
position in life in the context of the culture and value
systems of the countries in which they live and in relationship to their goals, expectations, standards and concerns’,
and health-related quality of life (HRQL) as ‘the physical,
emotional and social aspects of quality of life influenced by
an individual’s disease and/or its treatment’ [16]. During
the last 10 years, there has been a dramatic increase in the
development and utilization of paediatric HRQL measures
in an effort to improve paediatric patient health and wellbeing [17]. However, very few studies have measured the
impact that ADRs have on the quality of life of children
who have received any kind of drug therapy [18–22].
Therefore, the objective of this review was to explore what
is known in this area in the paediatric population.

Methods
We conducted a systematic review of studies evaluating
quality of life in children presenting ADRs. The search
focused on all publications describing or potentially
describing a study that evaluated or measured QoL or
HRQL in children suffering ADRs. The search included the
following electronic databases: MEDLINE, EMBASE (both
using the Ovid interface) and the Cochrane Library (including the Cochrane Database of Systematic Reviews, the
Database of Abstracts of Reviews of Effects, the Cochrane
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Controlled Trials Register and the Health Technology
Assessment Databases). The search was initially done in
March 2012 and updated in April 2014. The terms used
were ‘children’, ‘paediatric’, ‘quality of life’, ‘health-related
quality of life’ and ‘adverse drug reactions’ and were combined using Boolean operators. The strategy is available
from the authors upon request. No language or date
restrictions were considered. The retrieved references
were assessed by one reviewer for possible inclusion on
the basis of the evaluation of the title and the abstract, or
in full if no abstract was available. A second reviewer independently confirmed the final selection. Disagreements
were resolved by consensus. Finally, the bibliographies
from the retrieved studies were reviewed manually to
identify potential additional references.
We considered for inclusion any study using specific or
generic instruments to measure QoL or HRQL in paediatric
patients (0–18 years old) with a diagnosis of an ADR in any
condition. We excluded studies exclusively including
adults, studies evaluating only medical outcomes of the
ADRs or studies using nonstandardized measures of QoL,
owing to the potential risk for bias if nonstandardized
measures are used.
The objective was to describe the general impact of
ADRs on the QoL in children using a qualitative synthesis
approach. Data for each study were described separately.
A formal meta-analysis was not planned given the anticipated heterogeneous nature of the studies.

Results
Search results and characteristics of
included studies
The flow diagram of the review is shown in Figure 1. The
search indentified 131 records from the databases. Two
additional studies were identified through the review of
the bibliographies. Seventeen studies were evaluated
fully, and seven were excluded for the following reasons: in
two studies, the authors described characteristics of the
ADRs rather than the effects on the QoL of the patients; in
one study the authors evaluated QoL during active chemotherapy but not in relationship to ADRs; and in the rest of
the studies the authors failed to use standardized measures of HRQL (e.g. generic subjective assessments of wellbeing, such as ‘good health’ or ‘poor health’). We finally
included nine studies, which were described in 10 references and which included 1269 patients aged 3–18 years
(Table 2).
All studies but one were observational. The quality of
the studies was not assessed owing to the lack of a validated instrument for this particular type of study. Of the
nine studies that were included, six were found as a full
text, while three were published only in conference
abstracts (one study was reported in two abstracts). Four
of the studies were conducted among children with epi-

lepsy; the rest of them evaluated children with chronic
viral hepatitis, Crohn’s disease, cancer and multiple ADRs
compared with healthy children. Regarding the QoL
instruments, three were disease specific (USQOLCE, CAVE
and QOLIE-AD 48) and four were generic instruments
(PedsQL, CHQ-PF-50, Modified Sickness Impact and Rutter
Questionnaire). The age of the children among all the
studies ranged from 2 to 18 years. Sample sizes of the
studies were also diverse, ranging from 16 to 550 patients.
Most of the instruments were responded by parents or
caregivers, except for the QOLIE-AD 48, which is specifically designed to be answered by children between 11 and
18 years of age, and the studies conducted in adolescents
with cancer, in which the PedsQL was used.

Qualitative assessment of study findings
Although the characteristics of patients and the instruments used to measure QoL were heterogeneous, all
studies had similar conclusions; regardless of the condition
studied or the instrument used, ADRs had a negative effect
on the QoL of children. Additionally, several studies suggested that the severity and frequency of ADRs were also
associated with poorer QoL. Studies conducted in children
with epilepsy constituted the largest group and included
the largest number of patients. All studies concluded that
ADRs, including side-effects, had a negative impact on the
patients’ QoL, and one study suggested that the proper
selection of anticonvulsants reduced ADRs and thus
improved the QoL of children with this condition. Among
patients with paediatric neoplasias, the occurrence of
chemotherapy-induced side-effects was associated with
lower QoL accross several domains of the PedsQL scale.
This seemed to be independent of the effects of the cancer
itself on QoL, and patients experiencing more severe sideeffects had larger detrimental effects of their QoL. The
other studies mentioned that ADRs significantly deteriorated the HRQL of children with chronic viral hepatitis
undergoing α-interferon treatment, and side-effects of the
treatment in children with Crohn’s disease are the main
concern of their parents or caregivers regarding their children’s quality of life. Finally, one study showed that children with multiple ADRs have lower HRQL than children
with only one event of ADR.

Discussion
The development of new drug therapies has resulted in
increased survival and improved quality of life in adults
and children with diseases that were considered fatal or
disabling in the past. Unfortunately, highly effective drugs
are also associated with the risk of adverse reactions,
which can negatively affect QoL. The present study found
that studies evaluating HRQL or QoL in children with ADR
are very scarce. We were able to retrieve only nine studies
that measured HRQL or QoL and its relationship with ADRs
Br J Clin Pharmacol
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Records identified through

Additional records identified

database searching

through other sources

(n = 131)

(n = 2)

Records after duplicates removed

Screening

(n = 130)

Records screened

Records excluded

(n = 130)

(n = 113)

Eligibility

Full-text articles excluded (n = 7)
for the following reasons:
Full-text articles assessed

Studies describing only ADRs (n = 2)

for eligibility*

Study not assessing ADRs (n = 1)

(n = 17)

Studies using nonstandardized
HRQL measurements (n = 4)

Studies included in
qualitative synthesis†

Included

(n = 9)

Studies included in
quantitative synthesis
(meta-analysis)
(n = 0)

Figure 1
Flow diagram of the systematic review. Abbreviations are as follows: ADRs, adverse drug reactions; HRQL, health-related quality of life. *Four references
were available only in abstract form. †The final number of included references was 10, comprising nine studies. One study was reported twice in consecutive
years

in paediatric populations. Certainly, this represents only a
minute percentage among all studies published in children evaluating either HRQL or ADRs. However, all studies
concluded that ADRs result in a lower quality of life in
children in different settings.
The interest in HRQL/QoL in children has increased in
recent years. Clarke and Eiser [23] reported that QoL is
most frequently included in trials in diseases such as
asthma, rhinitis and dermatitis (eczema), perhaps because
830
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of the high incidence of these conditions, as well as other
chronic conditions, such as cancer, epilepsy and diabetes.
Interestingly, as we observed in our study, the impact of
ADRs among children with epilepsy has been studied
slightly more commonly than in other chronic diseases;
this may be related to the fact that antiepileptic therapy
has been associated with a high incidence of intolerable
side-effects and severe ADRs that affect the adherence to
treatment [24]. The findings of several studies agree that
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Table 2
Studies evaluating quality of life in children with adverse drug reactions

Study, country

Drug involved

Study design

Population studied

HRQL/QoL instrument

Main findings

Rabbett et al.
(1996), England
[34]

Not specified

Randomized cross-sectional
study

16 children aged 8–17 years
with Crohn’s disease

Rutter A Questionnaire

Iorio et al. (1997),
Italy [35]

α-Interferon

Prospective cohort

94 children aged 3–14 years
with chronic viral hepatitis

Modified sickness impact
profile

Side-effects of treatment are
the parents’ main concern
regarding their children’s
QoL. Adverse drug
reactions were associated
with lower QoL
Health-related quality of life
deteriorated significantly
during α-interferon therapy

Bellaire et al.
(2005), Canada
[18]
Morita et al.
(2007), USA [25]

Miscellaneous

Retrospective cohort

Parent-Form 50 (CHQ-PF50)

Carbamazepine and
valproic acid

Prospective cohort

42 children aged 5–17 years
with one ADR vs. multiple
ADRs
37 children of mean age 7.2
years with new-onset
epilepsy

Virag et al. (2010),
Slovakia [36]

Carbamazepine and
valproic acid and
others
Carbamazepine and
valproic acid

Retrospective, prospective
cohort

293 children with epilepsy
(mean age 12.9 years)

QOLIE-AD-48 (Slovak
version)

Longitudinal prospective
study

124 children aged 2–12 years
with newly diagnosed
epilepsy

PedsQL

Arslan et al. (2013),
Turkey [37]

Various
chemotherapeutic
agents

Cross-sectional study

93 children aged 10–18 years
with leukaemia, lymphoma
or solid tumours

PedsQL 4.0

Erickson et al.
(2011), USA [38]

Various
chemotherapeutic
agents

Prospective cohort

20 children aged 12–19 years
with leukaemia, lymphoma
or solid tumours

PedsQL

Lara-Herguedas
et al. (2011,
2013), Spain
[39, 40]

Miscellaneous

Observational, cross-sectional,
multicentre study

550 children aged <18 years
with epilepsy

Quality of life scale CAVE
and modified LAEP

Modi et al. (2011),
USA [26]

PedsQL and USQOLCE

Children with multiple ADRs
had a lower HRQL than
children with one ADR
Severe ADR/side-effects were
inversely related to QoL
Adverse effects of
antiepileptilc drugs
correlated with QoL
Side-effects from
anticonvulsants were
negatively associated with
all HRQL domains
The occurrence of
chemotherapy-related
symptoms/side-effects was
associated with lower QoL
Occurrence of
chemotherapy-related
fatigue was associated
with lower QoL
Adverse effects of
antiepileptics were inversely
associated with QoL

Abbreviations are as follows: ADR, adverse drug reaction; CAVE, Quality of Life scale in childhood epilepsy; CHQ-PF50, Child Health Questionnaire; HRQL, health-related quality of
life; LAEP, Liverpool Adverse Events Profile; PedsQL, Pediatric Quality of Life Inventory; QoL, quality of life; QOLIE-AD-48, Quality Of Life In Epilepsy for Adolescents; USQOLCE,
American Quality of Life in Childhood Epilepsy Questionnaire.

more severe antiepileptic drug side-effects are associated
with lower quality of life [25–27]. The information regarding HRQL and its relationship with ADRs in other settings
or conditions is virtually non-existent. Given that the
profile of the adverse reactions varies between drugs,
studies evaluating the impact of ADRs in other pathologies
are needed.
Interest has been scant among ADR researchers to
study the effects of ADRs on the quality of life in children.
Even in adults, there are very few studies interested in
health-related quality of life and ADRs [28, 29]. In general,
studies regarding drug therapies and drug effects related
to the quality of life of children would be expected to show
an improvement of symptoms or absence of disease. Nevertheless, in some cases when drug therapies produce
serious adverse reactions that may affect the quality of life
of children, studies focus only on the physical or health
impact rather than on the evaluation of all the aspects
(physical, emotional and social) of the children’s life [30].

Our study has several limitations that need to be noted.
First, indexing in databases might be suboptimal for this
type of study, because in some of the retrieved studies QoL
and HRQL were not the main study outcome. However, we
used MeSH terms in our search and we believe that they
should have captured the majority of studies. Second, the
quality of the studies could not be assessed properly
owing to a lack of validated scales for the assessment of
this type of study. Scales exist for assessing the quality of
observational studies in epidemiology, but their design is
focused on other types of outcomes. Third, we were
unable to conduct a quantitative analysis of the information owing to the heterogeneity of conditions, instruments
and study designs. Furthermore, while all studies concluded that ADRs adversely affected QoL and HRQL, there
is no standard measure of effect size, and many studies did
not include healthy control subjects. Fourth, QoL and
HRQL are also adversely affected by chronic and acute
disease, and confounding derived from the underlying
Br J Clin Pharmacol
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pathologies cannot be excluded entirely. Fifth, the ADRs
and side-effects reported in the included studies were
widely variable (ranging from fatigue, nausea and vomiting to erythroderma and Stevens–Johnson syndrome) and
their impact on QoL is different; however, some studies
assessed the severity of the ADRs using validated classifications and concluded that the more severe the ADR, the
higher the impact. Finally, the instruments used have
inherent limitations to detect changes in HRQL. There are
many instruments that help researchers to evaluate
quality of life in children [1, 31, 32]. In general, HRQL instruments can be divided into specific and generic. Generic
instruments are designed to assess and compare health
status in patients with different diseases and may provide
valuable information for comparing outcomes between
sick and healthy populations; they lack sensitivity to detect
small but clinically significant changes in HRQL over time
or due to treatment for specific diseases [1, 33]. Diseasespecific measures are more suitable for evaluation of clinical trials designed to assess a particular treatment. These
measures include items that are likely to be affected by the
specific disease or treatment and are therefore more
responsive to clinically significant changes [23, 33].
In conclusion, despite recent interest in HRQL, we
found that there is very little information about quality of
life among children with ADRs. Notwithstanding the considerable economic and epidemiological impact that ADRs
have worldwide, there is still low interest shown by physicians and healthcare providers to report common ADRs
and also to study objectively their effects on the quality of
life of these children and their parents. It is therefore a
challenge for those interested in this topic to develop
studies and tools to help us increase the knowledge and
understanding about ADRs and their consequences, with
the final objective of improving methods and strategies for
early identification and prevention of ADRs and, in this
way, decreasing the morbidity and mortality associated
with them.
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